Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue

Lu,Qingjun; Wang,Jieshu; Yu,Gang; Guo,Tianhua; Hu,Chun; Ren,Peng

doi:10.3892/ol.2015.3228

Expression and clinical significance of mammalian target of rapamycin/P70 ribosomal protein S6 kinase signaling pathway in human colorectal carcinoma tissue

Authors:
- Qingjun Lu
- Jieshu Wang
- Gang Yu
- Tianhua Guo
- Chun Hu
- Peng Ren
View Affiliations

Affiliations: Department of General Surgery, Binzhou Central Hospital, Binzhou Medical College, Binzhou, Shandong, P.R. China, Department of Oncology, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, P.R. China
Published online on: May 19, 2015 https://doi.org/10.3892/ol.2015.3228
Pages: 277-282

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The activation of mammalian target of rapamycin (mTOR) has been reported in tumor development, but the role of mTOR in colorectal carcinomas remains unclear. The aim of the present study was to investigate the significance of mTOR and its downstream effector 70 kDa ribosomal protein S6 kinase (P70S6K) in human colorectal carcinomas. The phosphorylated (p‑)mTOR and p‑P70S6K proteins were examined by immunohistochemistry performed on tissue microarray containing tissue samples obtained from colorectal carcinoma (n=111), adenomatous polyps (n=40) and normal colonic mucosa (n=40), with a comparison between the expression of these proteins and the clinicopathological parameters of patients with carcinomas. The positive expression rates of p‑mTOR and p‑P70S6k were 60.4 and 65.8%, respectively, in colorectal carcinoma tissue, which was significantly increased compared with the tissue from adenomatous polyps (27.5 and 20%, respectively) and normal colonic mucosa (10.0 and 5.0%, respectively) (P<0.05). Overexpression of the p‑mTOR and p‑P70S6K proteins was significantly associated with the tumor‑node‑metastasis stage, the occurrence of distal and lymph node metastasis and the degree of differentiation. Aberrant expression of p‑mTOR and p‑P70S6K may contribute to the pathogenesis, growth, invasion and metastasis of colorectal carcinoma. The phosphorylation of these proteins was considered to be a promising marker to indicate the aggressive behaviors and prognosis of colorectal carcinomas. The overexpression of the mTOR/P70S6K signaling pathway may play an important role in colorectal carcinoma carcinogenesis. The expression of p‑mTOR and p‑P70S6K was considered as a promising marker to indicate the aggressive behaviors and prognosis of human colorectal carcinomas.

View Figures

View References

1	World Health Organization, . The Global Burden of Disease: 2004 Update. World Health Organization; Geneva: 2008
2	Ferlay J, Shin HR, Bray F, et al: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Otake S, Takeda H, Fujishima S, et al: Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol. 16:1252–1257. 2010. View Article : Google Scholar : PubMed/NCBI
4	Buck E, Eyzaguirre A, Brown E, et al: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther. 5:2676–2684. 2006. View Article : Google Scholar : PubMed/NCBI
5	Pene F, Claessens YE, Muller O, et al: Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 21:6587–6597. 2002. View Article : Google Scholar : PubMed/NCBI
6	Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI
7	Foster DA: Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells. Biochim Biophys Acta. 1791:949–955. 2009. View Article : Google Scholar : PubMed/NCBI
8	Jiang BH and Liu LZ: Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment. Drug Resist Updat. 11:63–76. 2008. View Article : Google Scholar : PubMed/NCBI
9	Wang X and Proud CG: The mTOR pathway in the control of protein synthesis. Physiology (Bethesda). 21:362–369. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kim EK, Kim HA, Koh JS, et al: Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 126:93–99. 2011. View Article : Google Scholar : PubMed/NCBI
11	Han D, Li SJ, Zhu YT, et al: LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev. 14:4033–4039. 2013. View Article : Google Scholar : PubMed/NCBI
12	Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 22:2336–2347. 2004. View Article : Google Scholar : PubMed/NCBI
13	O’Donnell A, Faivre S, Burris HA III, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 26:1588–1595. 2008. View Article : Google Scholar : PubMed/NCBI
14	Rizell M, Andersson M, Cahlin C, et al: Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol. 13:66–70. 2008. View Article : Google Scholar : PubMed/NCBI
15	Benson AB III, Bekaii-Saab T, Chan E, et al: National Comprehensive Cancer Network: Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 11:519–528. 2013.PubMed/NCBI
16	Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T and Sugihara K: Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer. 100:782–788. 2009. View Article : Google Scholar : PubMed/NCBI
17	Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R and Filipits M: Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res. 13:4795–4799. 2007. View Article : Google Scholar : PubMed/NCBI
18	Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW and Tsao MS: Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer. 8:432008. View Article : Google Scholar : PubMed/NCBI
19	Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S and Ooi A: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer. 115:107–118. 2009. View Article : Google Scholar : PubMed/NCBI
20	Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology. 58:1054–1063. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA and Nagle RB: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
22	Feng W, Duan X, Liu J, Xiao J and Brown RE: Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol. 2:249–260. 2009.PubMed/NCBI
23	Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A and Duffy MJ: mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors. Breast. 21:178–182. 2012. View Article : Google Scholar : PubMed/NCBI
24	Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O’Toole T, Gibbons J, Belldegrun AS and Figlin RA: Prognostic relevance of the mTOR pathway in renal cell carcinoma: Implications for molecular patient selection for targeted therapy. Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
25	Chung JY, Hong SM, Choi BY, Cho H, Yu E and Hewitt SM: The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res. 15:660–667. 2009. View Article : Google Scholar : PubMed/NCBI
26	Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC and Xie K: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 15:1821–1829. 2009. View Article : Google Scholar : PubMed/NCBI
27	Wang D, Chen J, Guo F, Chen H, Duan Z, Wei MY, Xu QM, Wang LH and Zhong MZ: Clinical significance of mTOR and p-mTOR protein expression in human colorectal carcinomas. Asian Pac J Cancer Prev. 12:2581–2584. 2011.PubMed/NCBI
28	No JH, Jeon YT, Park IA, Kang D, Kim JW, Park NH, Kang SB and Song YS: Expression of mTOR protein and its clinical significance in endometrial cancer. Med Sci Monit. 15:BR301–BR305. 2009.PubMed/NCBI
29	Berven LA, Willard FS and Crouch MF: Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res. 296:183–195. 2004. View Article : Google Scholar : PubMed/NCBI
30	Contessa JN, Hampton J, Lammering G, et al: Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene. 21:4032–4041. 2002. View Article : Google Scholar : PubMed/NCBI
31	Xiao L, Wang YC, Li WS and Du Y: The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: An immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 28:1522009. View Article : Google Scholar : PubMed/NCBI
32	Zhang Y, Ni HJ and Cheng DY: Prognostic value of phosphorylated mTOR/RPS6KB1 in non- small cell lung cancer. Asian Pac J Cancer Prev. 14:3725–3728. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ji J and Zheng PS: Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecol Oncol. 117:103–108. 2010. View Article : Google Scholar : PubMed/NCBI
34	Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N and Dormond O: Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer. 9:572010. View Article : Google Scholar : PubMed/NCBI